miRview® squamous is a cutting-edge molecular diagnostic test that uses microRNA to differentiate between squamous and nonsquamous NSCLC. The test offers unsurpassed accuracy, specificity, and sensitivity. Based on a post-approval validation study, miRview® squamous demonstrated 100% sensitivity and specificity for the diagnosis of squamous versus nonsquamous NSCLC¹. Click here for the study design



Figure. (A) For lung cancer resections, the reference score of 2.5 was found to have 100% sensitivity and 100% specificity in differentiating squamous cell carcinomas (SqCCs) and adenocarcinomas. (B)Similar precision of sensitivity and specificity was seen with preoperative biopsies and aspirates. Figure reprinted with permission from the American Association for Cancer Research. Figure 2 from Bishop JA, Benjamin H, Cholakh H, Chajat A, Clark DP, Westra WH. Accurate classification of non–small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res. 2010;16(2):610-619.

miRview® squamous provides classification precision even in poorly differentiated tumors. Precise classification was even seen with limited tumor sampling. Click here for the case study

miRview® squamous accurately classifies squamous and nonsquamous NSCLC

• The sensitivity of miRview® squamous for identifying SqCC in the resection specimens was 100%
• The specificity of miRview® squamous for classifying tumors as nonsquamous was 100%

miRview® squamous measures the expression level of a single microRNA biomarker, so the results are easy to interpret. A score below 2.5 is interpreted as evidence of squamous histology. A score above 2.5 is interpreted as evidence of nonsquamous histology.

Download Sample Report

1. Bishop JA, Benjamin H, Cholakh H, Chajat A, Clark DP, Westra WH. Accurate classification of non–small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res. 2010;16(2):610-619.